Serological criteria and carriage measurement for evaluation of new pneumococcal vaccines

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 6, 2015, Pages 1494-1500

  Principi, Nicola ^a   Esposito, Susanna ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Correlate of protection; Pneumococcal carriage; Pneumococcal colonisation; Pneumococcal conjugate vaccine; Pneumococcal vaccination; Streptococcus pneumonia; Vaccine efficacy

Indexed keywords

PNEUMOCOCCUS VACCINE; BACTERIUM ANTIBODY;

ARTICLE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; INCIDENCE; NONHUMAN; SEROLOGY; STREPTOCOCCUS PNEUMONIAE; BLOOD; HETEROZYGOTE; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; NASOPHARYNX; PNEUMOCOCCAL INFECTIONS; PREVENTION AND CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SERUM BACTERICIDAL ACTIVITY; TREATMENT OUTCOME;

ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; CARRIER STATE; HUMANS; INFANT; NASOPHARYNX; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 84944461136     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1033600     Document Type: Article

References (64)

1. Chen RT, Orenstein WA. Epidemiologic methods in immunization programs. Epidemiol Rev 1996; 18:99- 117; PMID:9021306; http://dx. doi. org/10. 1093/ oxfordjournals. epirev. a017931
2. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17:1055- 65; PMID:20463105; http://dx. doi. org/10. 1128/ CVI. 00131-10
3. Ellis RW, Granoff DM, Frasch CE. Regulatory perspectives in vaccine licensure. In: Ellis RW, Granoff DM, editors. Development and Clinical uses of Haemophilus b Conjugate Vaccines. New York: Marcel Dekker; 1994:435-53.
4. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003; 10:780-6; PMID:12965904
5. World Health Organization. Recommendations for the production and control pf pneumococcal conjugate vaccineess. WHO Tech Rep Ser 2005; 927:1-154; PMID:16454167
6. Vila-Corcoles A, Ochoa-Gondar O. Pneumococcal conjugate vaccination: correlates of protection. Lancet Infect Dis 2014; 14:784-6; PMID:25042757; http:// dx. doi. org/10. 1016/S1473-3099(14)70849-7
7. Jódar L, Butler J, Carlone G, Dagan R, Goldblatt D, Käyhty H, Klugman K, Plikaytis B, Siber G, Kohberger R, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003; 21:3265-72; http:// dx. doi. org/10. 1016/S0264-410X(03)00230-5
8. Auranen K, Rinta-Kokko H, Goldblatt D, Nohynek H, O'Brien KL, Satzke C, Simell B, Tanskanen A, Käyhty H; Pneumococcal Carriage Group (PneumoCarr). Colonisation endpoints in Streptococcus pneumoniae vaccine trials. Vaccine 2013; 32:153-8; PMID:24016803; http://dx. doi. org/10. 1016/j. vaccine. 2013. 08. 061
9. Weil-Olivier C, Gaillat J. Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults? Vaccine 2014; 32:2022-6; PMID:24565755; http://dx. doi. org/10. 1016/j. vaccine. 2014. 02. 008
10. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187-95; PMID:10749457; http://dx. doi. org/ 10. 1097/00006454-200003000-00003
11. O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, Kumar G, Parkinson A, Hu D, Hackell J, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003; 362:355-61; PMID:12907008
12. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349:1341-8; PMID:14523142; http://dx. doi. org/ 10. 1056/NEJMoa035060
13. Nahm MH, Olander JV, Magyarlaki M. Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae. J Infect Dis 1997; 176:698-703; PMID:9291318; http://dx. doi. org/10. 1086/514093
14. Gomez-Lus ML, Giménez MJ, Vázquez JA, Aguilar L, Anta L, Berrón S, Laguna B, Prieto J. Opsonophagocytosis versus complement bactericidal killing as effectors following Neisseria meningitidis group C vaccination. Infection 2003; 31:51-4; PMID:12590334; http://dx. doi. org/10. 1007/s15010-002-3128-4
15. Lee LH, Frasch CE, Falk LA, Klein DL, Deal CD. Correlates of immunity for pneumococcal conjugate vaccines. Vaccine 2003; 21:2190-6; PMID:12706710; http://dx. doi. org/10. 1016/S0264-410X(03)00025-2
16. Balloch A, Licciardi PV, Leach A, Nurkka A, Tang ML. Results from an inter-laboratory comparison of pneumococcal serotype-specific IgG measurement and critical parameters that affect assay performance. Vaccine 2010; 28:1333-40; PMID:19932671; http://dx. doi. org/10. 1016/j. vaccine. 2009. 11. 011
17. Deloria Knoll M, Park DE, Johnson TS, Chandir S, Nonyane BA, Conklin L, Fleming-Dutra KE, Loo JD, Goldblatt D, Whitney CG, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity. Pediatr Infect Dis J 2014; 33 Suppl 2:S119-29; PMID:24336054; http://dx. doi. org/10. 1097/ INF. 0000000000000079
18. Pichichero ME. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother 2013; 9:2505-23; PMID:23955057; http://dx. doi. org/10. 4161/hv. 26109
19. Esposito S, Pugni L, Bosis S, Proto A, Cesati L, Bianchi C, Cimino C, Mosca F, Principi N. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine 2005; 23:1703-8; PMID:15705475; http://dx. doi. org/ 10. 1016/j. vaccine. 2004. 09. 029
20. Deloria Knoll M, Park DE, Johnson TS, Chandir S, Nonyane BA, Conklin L. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity. Pediatr Infect Dis J 2014; 33 Suppl 2:S119-29; PMID:24336054; http://dx. doi. org/ 10. 1097/INF. 0000000000000079
21. Cortese MM, Wolff M, Almeido-Hill J, Reid R, Ketcham J, Santosham M. High incidence rates of invasive pneumococcal disease in the White Mountain Apache population. Arch Intern Med 1992; 152:2277-82; PMID:1444688; http://dx. doi. org/ 10. 1001/archinte. 1992. 00400230087015
22. Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, Slack M, Ladhani SN, Miller E, Goldblatt D. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis 2014; 14:839-46; PMID:25042756; http:// dx. doi. org/10. 1016/S1473-3099(14)70822-9
23. Ruiz-Aragón J, Márquez Peláez S, Molina-Linde JM, Grande-Tejada AM. Safety and immunogenicity of 13- valent pneumococcal conjugate vaccine in infants: a meta-analysis. Vaccine 2013; 31:5349-58; http://dx. doi. org/10. 1016/j. vaccine. 2013. 09. 008
24. Melin M, Jarva H, Siira L, Meri S, Kayhty H, Vakevainen M. Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B. Infect Immun 2009; 77:676-84; PMID:19047408; http://dx. doi. org/ 10. 1128/IAI. 01186-08
25. Pichichero ME. Otitis media. Pediatr Clin North Am 2013; 60:391-407; PMID:23481107; http://dx. doi. org/10. 1016/j. pcl. 2012. 12. 007
26. Cardinale F, Cappiello AR, Mastrototaro MF, Pignatelli M, Esposito S. Community-acquired pneumonia in children. Early Hum Dev 2013; 89 Suppl 3:S49-52; PMID:23962481; http://dx. doi. org/10. 1016/j. earlhumdev. 2013. 07. 023
27. Mehr S, Wood N. Streptococcus pneumoniae - a review of carriage, infection, serotype replacement and vaccination. Paediatr Respir Rev 2012; 13:258- 64; PMID:23069126; http://dx. doi. org/10. 1016/j. prrv. 2011. 12. 001
28. Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis 2012; 12:207; PMID:22954038; http://dx. doi. org/10. 1186/1471- 2334-12-207
29. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A, Käyhty H, Karma P, Kohberger R, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344:403-9; PMID:11172176; http://dx. doi. org/ 10. 1056/NEJM200102083440602
30. Jokinen JT, Ahman H, Kilpi TM, Mäkelä PH, Käyhty MH. Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J Infect Dis 2004; 190:545-50; PMID:15243930; http://dx. doi. org/10. 1086/422531
31. Ekström N, Väkeväinen M, Verho J, Kilpi T, Käyhty H. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial. Infect Immun 2007; 75:1794- 800; PMID:17261612; http://dx. doi. org/10. 1128/ IAI. 01673-06
32. Goldblatt D, Ramakrishnan M, O'Brien K. Using the impact of pneumococcal vaccines on nasopharyngeal carriage to aid licensing and vaccine implementation; A Pneumocarr meeting report March 27-28, 2012, Geneva. Vaccine 2013; 32:146-52; PMID:23933374; http://dx. doi. org/10. 1016/j. vaccine. 2013. 06. 040
33. Simell B, Auranen K, Käyhty H, Goldblatt D, Dagan R, O'Brien KL. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines 2012; 11:841-55; PMID:22913260; http://dx. doi. org/ 10. 1586/erv. 12. 53
34. Gray BM, Converse GM 3rd, Dillon HC Jr. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis 1980; 142:923-33; PMID:7462701; http://dx. doi. org/10. 1093/infdis/ 142. 6. 923
35. Sleeman KL, Daniels L, Gardiner M, Griffiths D, Deeks JJ, Dagan R, Gupta S, Moxon ER, Peto TE, Crook DW. Acquisition of Streptococcus pneumoniae and nonspecific morbidity in infants and their families: a cohort study. Pediatr Infect Dis J 2005; 24:121-7; PMID:15702039; http://dx. doi. org/10. 1097/01. inf. 0000151030. 10159. b1
36. Hill PC, Cheung YB, Akisanya A, Sankareh K, Lahai G, Greenwood BM, Adegbola RA. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian infants: a longitudinal study. Clin Infect Dis 2008; 46:807-14; PMID:18279039; http://dx. doi. org/ 10. 1086/528688
37. Syrjänen RK, Herva EE, Mäkelä PH, Puhakka HJ, Auranen KJ, Takala AK, Kilpi TM. The value of nasopharyngeal culture in predicting the etiology of acute otitis media in children less than two years of age. Pediatr Infect Dis J 2006; 25:1032-6; http://dx. doi. org/10. 1097/01. inf. 0000241097. 37428. 1d
38. Kamme C, Lundgren K, Märdh PA. The aetiology of acute otitis media in children. Occurrence of bacteria, L forms of bacteria and mycoplasma in the middle ear exudate. Relationship between bacterial findings in the middle ear exudate, nasopharynx and throat. Scand J Infect Dis 1971; 3:217-23; PMID:4399782; http://dx. doi. org/10. 3109/inf. 1971. 3. issue-3. 07
39. Eldan M, Leibovitz E, Piglansky L, Raiz S, Press J, Yagupsky P, Leiberman A, Dagan R. Predictive value of pneumococcal nasopharyngeal cultures for the assessment of nonresponsive acute otitis media in children. Pediatr Infect Dis J 2000; 19:298-03; PMID:10783018; http://dx. doi. org/10. 1097/ 00006454-200004000-00007
40. Myint TT, Madhava H, Balmer P, Christopoulou D, Attal S, Menegas D, Sprenger R, Bonnet E. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther 2013; 30:127-51; PMID:23397399; http://dx. doi. org/ 10. 1007/s12325-013-0007-6
41. Loo JD, Conklin L, Fleming-Dutra KE, Deloria Knoll M, Park DE, Kirk J, Goldblatt D, O'Brien KL, Whitney CG. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. Pediatr Infect Dis J 2014; 33 Suppl 2: S140-51; PMID:24336056; http://dx. doi. org/ 10. 1097/INF. 0000000000000082
42. Principi N, Baggi E, Esposito S. Prevention of acute otitis media using currently available vaccines. Future Microbiol 2012; 7:457-65; PMID:22439723; http:// dx. doi. org/10. 2217/fmb. 12. 23
43. Fleming-Dutra KE, Conklin L, Loo JD, Knoll MD, Park DE, Kirk J, Goldblatt D, Whitney CG, O'Brien KL. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage. Pediatr Infect Dis J 2014; 33 Suppl 2:S152-60; PMID:24336057; http://dx. doi. org/ 10. 1097/INF. 0000000000000083
44. Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012; 31:297-301; PMID:22330166; http://dx. doi. org/ 10. 1097/INF. 0b013e318247ef84
45. Loughlin AM, Hsu K, Silverio AL, Marchant CD, Pelton SI. Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts' children. Pediatr Infect Dis J 2014; 33:504-10; PMID:24670957; http://dx. doi. org/10. 1097/INF. 0000000000000279
46. Ghaffar F, Barton T, Lozano J, Muniz LS, Hicks P, Gan V, Ahmad N, McCracken GH Jr. Effect of 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 2004; 39:930-8; PMID:15472842; http://dx. doi. org/10. 1086/423379
47. Hennessy TW, Singleton, Bulkow LR, Bruden DL, Hurlburt DA, Parks D, Moore M, Parkinson AJ, Schuchat A, Butler JC. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a healthy disparity. Vaccine 2005; 23:5464-73; PMID:16188350; http://dx. doi. org/10. 1016/j. vaccine. 2005. 08. 100
48. Huang S, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann S, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 2005; 116: e408-e413; PMID:16140686; http://dx. doi. org/ 10. 1542/peds. 2004-2338
49. Mbelle N, Huebner RE, Wasas AD, Kimura A, Chang I, Klugman KP. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999; 180:1171-6; PMID:10479145; http://dx. doi. org/ 10. 1086/315009
50. O'Brien KL, Millar EV, Zell ER, Bronsdon M, Weatherholtz R, Reid R, Becenti J, Kvamme S, Whitney CG, Santosham M. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a communityrandomized trial. J Infect Dis 2007; 196:1211-20; PMID:17955440; http://dx. doi. org/10. 1086/521833
51. Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005; 54:893-7; PMID:16163262
52. Dagan R. Serotype replacement in perspective. Vaccine 2009; 27(Suppl. 3):c22-4; PMID:19545935; http://dx. doi. org/10. 1016/j. vaccine. 2009. 06. 004
53. Principi N, Esposito S. Use of the 13-valent pneumococcal conjugate vaccine in infants and young children. Expert Opin Biol Ther 2012; 12:641-8; PMID:22397739; http://dx. doi. org/10. 1517/ 14712598. 2012. 670217
54. Dagan R, Givon-Lavi N, Zamir O, Fraser D. Effect of a nonavalent conjugate vaccine on carriage of antibiotic- resistant Streptococcus pneumoniae in day-care centers. Pediatr Infect Dis J 2003; 22:532-40; PMID:12799510
55. Dagan R, Givon-Lavi N, Porat N, Greenberg D. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-alent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial. Vaccine 2012; 30:5132- 40; PMID:22683519; http://dx. doi. org/10. 1016/j. vaccine. 2012. 05. 059
56. Rinta-Kokko H, Dagan R, Givon-Lavi N, Auranen K. Estimation of vaccine efficacy against acquisition of pneumococcal carriage. Vaccine 2009; 27:3831- 7; PMID:19490983; http://dx. doi. org/10. 1016/j. vaccine. 2009. 04. 009
57. Scott P, Herzog SA, Auranen K, Dagan R, Low N, Egger M, Heijne JC. Timing of bacterial carriage sampling in vaccine trials: a modelling study. Epidemics 2014; 9:8-17; PMID:25480130; http://dx. doi. org/ 10. 1016/j. epidem. 2014. 08. 003
58. Auranen K, Rinta-Kokko H, Halloran ME. Estimating strain-specific and overall efficacy of polyvalent vaccines against recurrent pathogens from a cross-sectional study. Biometrics 2013; 69:235-44; PMID:23379663; http://dx. doi. org/10. 1111/j. 1541-0420. 2012. 01826. x
59. Cvitkovic Spik V, Beovic B, Pokorn M, Drole Torkar A, Vidmar D, Papst L, Seme K, Kogoj R, Müller Premru M. Improvement of pneumococcal pneumonia diagnostics by the use of rt-PCR on plasma and respiratory samples. Scand J Infect Dis 2013; 45:731-7; PMID:23826792; http://dx. doi. org/10. 3109/00365548. 2013. 804631
60. O'Brien KL, Nohynek H. World health organization pneumococcal vaccine trials carriage working group. Report from a WHO working group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J 2003; 22:133-40
61. Principi N, Terranova L, Zampiero A, Manzoni F, Senatore L, Rios WP, Esposito S. Oropharyngeal and nasopharyngeal sampling for the detection of adolescent Streptococcus pneumoniae carriers. J Med Microbiol 2014; 63:393-8; PMID:24298049; http://dx. doi. org/ 10. 1099/jmm. 0. 068726-0
62. Trzciński K, Bogaert D, Wyllie A, Chu ML, van der Ende A, Bruin JP, van den Dobbelsteen G, Veenhoven RH, Sanders EA. Superiority of trans-oral over transnasal sampling in detecting Streptococcus pneumoniae colonization in adults. PLoS One 2013; 8:e60520; PMID:23555985; http://dx. doi. org/10. 1371/journal. pone. 0060520
63. Principi N, Terranova L. Zampiero A, Montinaro V, Ierardi V, Peves Rios W, Pelucchi C, Esposito S. Pharyngeal colonisation by Streptococcus pneumoniae in older children and adolescents in a geographical area characterised by relatively limited pneumococcal vaccination coverage. Pediatr iinfect Dis J 2014; in press; PMID:25760567
64. Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, Slack M, Ladhani SN, Miller E, Goldblatt D. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis 2014; 14:839-46; PMID:25042756; http:// dx. doi. org/10. 1016/S1473-3099(14)70822-9